Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Manhattan BioSolutions Announces Phase I SBIR Grant Award from the National Science Foundation

NEW YORK, NEW YORK, UNITED STATES, September 9, 2020 /EINPresswire.com/ — Manhattan BioSolutions, a biotechnology company focused on the discovery of the […]

Published March 10, 2022

Manhattan BioSolutions Announces Grant Award from the New Jersey CSIT

Fort Lee, New Jersey Mar 10, 2022 (Issuewire.com) – Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for […]

Published September 1, 2018

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

Published August 23, 2021

EVQLV and Manhattan BioSolutions Announce Grant Award from UB CAT

New York City, New York Jun 29, 2021 (Issuewire.com) – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University